Biomea Fusion Inc
NASDAQ:BMEA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biomea Fusion Inc
NASDAQ:BMEA
|
US |
|
Acarix AB
OTC:ACIXF
|
SE |
|
Bank Jago Tbk PT
IDX:ARTO
|
ID |
|
FirstRand Ltd
OTC:FANDF
|
ZA |
|
James Hardie Industries PLC
F:JHA0
|
IE |
|
W
|
Wix.Com Ltd
F:W1X
|
IL |
|
D
|
Digital Workforce Services Oyj
F:DQ4
|
FI |
|
S
|
Sumitomo Rubber Industries Ltd
F:108
|
JP |
|
A
|
Amphenol Corp
F:XPH
|
US |
|
Q
|
Qiagen NV
LSE:0RLT
|
NL |
|
S
|
Sino Land Co Ltd
XMUN:SNO
|
HK |
|
Bank Mandiri (Persero) Tbk PT
F:PQ90
|
ID |
|
W
|
Wiit SpA
F:9PC
|
IT |
|
Pinelawn Cemetery
OTC:PLWN
|
US |
Biomea Fusion Inc
Biomea Fusion is a clinical-stage biotechnology company that works on oral small-molecule medicines for serious diseases, especially diabetes and certain cancers. Its drug candidates are designed to bind tightly to specific disease-related proteins, with the goal of changing how those proteins work inside the body. The company does not sell approved products yet. It spends most of its effort on research, lab testing, and clinical trials, and it may eventually make money by selling an approved drug itself or by licensing its programs to larger drug companies. Its main customers, if successful, would be patients treated by doctors and hospitals, with health insurers and pharmacies also part of the sales chain. What makes Biomea different is its focus on covalent inhibitors, a class of drugs that form a lasting bond with their target. In simple terms, it is trying to build medicines that can shut down the right biological target more completely and for longer, which is a distinct approach within drug development.
Biomea Fusion is a clinical-stage biotechnology company that works on oral small-molecule medicines for serious diseases, especially diabetes and certain cancers. Its drug candidates are designed to bind tightly to specific disease-related proteins, with the goal of changing how those proteins work inside the body.
The company does not sell approved products yet. It spends most of its effort on research, lab testing, and clinical trials, and it may eventually make money by selling an approved drug itself or by licensing its programs to larger drug companies. Its main customers, if successful, would be patients treated by doctors and hospitals, with health insurers and pharmacies also part of the sales chain.
What makes Biomea different is its focus on covalent inhibitors, a class of drugs that form a lasting bond with their target. In simple terms, it is trying to build medicines that can shut down the right biological target more completely and for longer, which is a distinct approach within drug development.
